Loomis, Sayles & Company
GSK icon

Loomis, Sayles & Company’s GSK GSK Stock Holding History

Loomis, Sayles & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,569
Closed -$835K – 908
2018
Q2 		$835K Sell
16,569
-6,933
-29% -$349K ﹤0.01% 557
2018
Q1 		$1.15M Sell
23,502
-500
-2% -$23.3K ﹤0.01% 568
2017
Q4 		$1.06M Hold
24,002
– – ﹤0.01% 564
2017
Q3 		$1.22M Hold
24,002
– – ﹤0.01% 562
2017
Q2 		$1.29M Hold
24,002
– – ﹤0.01% 554
2017
Q1 		$1.26M Sell
24,002
-1,129
-4% -$57.3K ﹤0.01% 563
2016
Q4 		$1.21M Buy
25,131
+4,839
+24% +$239K ﹤0.01% 587
2016
Q3 		$1.09M Buy
20,292
+1,669
+9% +$91.5K ﹤0.01% 580
2016
Q2 		$1.01M Buy
18,623
+2,118
+13% +$112K ﹤0.01% 573
2016
Q1 		$837K Buy
16,505
+6,231
+61% +$310K ﹤0.01% 590
2015
Q4 		$518K Buy
10,274
+1,519
+17% +$77.4K ﹤0.01% 619
2015
Q3 		$421K Buy
8,755
+592
+7% +$30.8K ﹤0.01% 638
2015
Q2 		$425K Sell
8,163
-2,736
-25% -$154K ﹤0.01% 617
2015
Q1 		$629K Buy
10,899
+233
+2% +$13.4K ﹤0.01% 629
2014
Q4 		$570K Sell
10,666
-108,296
-91% -$6.06M ﹤0.01% 595
2014
Q3 		$6.84M Buy
118,962
+77,415
+186% +$4.75M 0.02% 523
2014
Q2 		$2.78M Sell
41,547
-236
-0.6% -$16K 0.01% 573
2014
Q1 		$2.79M Buy
41,783
+481
+1% +$32.5K 0.01% 560
2013
Q4 		$2.76M Buy
41,302
+15,957
+63% +$1.03M 0.01% 585
2013
Q3 		$1.59M Sell
25,345
-472
-2% -$30.4K 0.01% 599
2013
Q2 		$1.61K Buy
+25,817
New +$1.64M 0.01% 579

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Loomis, Sayles & Company's GSK Position: Q3 2018 in Review

Loomis, Sayles & Company sold out of GSK (GSK) in Q3 2018, closing a stake of 16,569 shares — an estimated $835K sold.

Loomis, Sayles & Company first reported a position in GSK in Q2 2013 and held it in 21 quarters. The position peaked at $6.84M in Q3 2014. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

  • Loomis, Sayles & Company reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 16,569 GSK shares in Q3 2018, an estimated $835K.
  • Loomis, Sayles & Company first reported a position in GSK in Q2 2013 and held it in 21 quarters.
  • Loomis, Sayles & Company's GSK position peaked at $6.84M in Q3 2014.
  • 787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Loomis, Sayles & Company's 13F filing for Q3 2018, filed 13 Nov 2018.